Home Cart Sign in  
Chemical Structure| 202914-84-9 Chemical Structure| 202914-84-9

Structure of Lomitapide mesylate
CAS No.: 202914-84-9

Chemical Structure| 202914-84-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lomitapide Mesylate is a MTTP inhibitor with IC50 of 8 nM, used as a complement to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia.

Synonyms: AEGR-733 mesylate; BMS-201038 mesylate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lomitapide mesylate

CAS No. :202914-84-9
Formula : C40H41F6N3O5S
M.W : 789.83
SMILES Code : O=C(C1(CCCCN2CCC(NC(C3=CC=CC=C3C4=CC=C(C(F)(F)F)C=C4)=O)CC2)C5=C(C6=C1C=CC=C6)C=CC=C5)NCC(F)(F)F.O=S(C)(O)=O
Synonyms :
AEGR-733 mesylate; BMS-201038 mesylate
MDL No. :MFCD19443682
InChI Key :QKVKOFVWUHNEBX-UHFFFAOYSA-N
Pubchem ID :11274333

Safety of Lomitapide mesylate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Panc-1 cells 3.5 μM, 1.75 μM, 0.875 μM 15 days Assess the effect of Lomitapide on colony formation of Panc-1 cells, results showed Lomitapide significantly inhibited colony formation in a dose-dependent manner Cell Death Discov. 2023 Feb 11;9(1):60.
SW1990 cells 2.786–7.293 μM Evaluate the inhibitory effect of Lomitapide on pancreatic cancer cell lines, results showed Lomitapide significantly inhibited cell proliferation Cell Death Discov. 2023 Feb 11;9(1):60.
SW480 colorectal cancer cells 0, 5 µM 48 h To evaluate the effect of Lomitapide on the colony formation of SW480 cells, results showed that Lomitapide significantly inhibited the colony formation of SW480 cells. Cell Death Dis. 2022 Jul 12;13(7):603.
HT29 colorectal cancer cells 0, 5 µM 48 h To evaluate the effect of Lomitapide on the colony formation of HT29 cells, results showed that Lomitapide significantly inhibited the colony formation of HT29 cells. Cell Death Dis. 2022 Jul 12;13(7):603.
HCT116 colorectal cancer cells 0, 1, 2, 5, 10 µM 24 h To evaluate the effect of Lomitapide on the viability of HCT116 cells, results showed that Lomitapide significantly reduced the viability of HCT116 cells. Cell Death Dis. 2022 Jul 12;13(7):603.
Neuro-2a cells 0.01, 0.1, and 1 μM 24 h Lomitapide alleviated cell damage caused by OGD and improved cell viability in a concentration-dependent manner. CNS Neurosci Ther. 2022 Dec;28(12):2183-2194.
Mouse primary neurons 0.01, 0.1, and 1 μM 24 h Lomitapide alleviated cell damage caused by OGD and improved cell viability in a concentration-dependent manner. CNS Neurosci Ther. 2022 Dec;28(12):2183-2194.
Human Umbilical Vein Endothelial Cells (HUVEC) 100 nM 24 h To dissect the direct effect of lomitapide on endothelial function and integrity, results showed that lomitapide did not reduce the damage in endothelial cells after palmitate treatment. Obesity (Silver Spring). 2022 Apr;30(4):893-901.
Staphylococcus aureus 12.5–50 μM 24 h Lomitapide exhibited broad-spectrum antibacterial activity against Gram-positive bacteria, including inhibition of planktonic cell growth and biofilm formation in Staphylococcus aureus. BMC Microbiol. 2022 Apr 26;22(1):114.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c female nude mice Mia PaCa-2 xenograft model Intraperitoneal injection 12 mg/kg, 8 mg/kg, 4 mg/kg Once daily for 3 weeks Evaluate the antitumor effect of Lomitapide in vivo, results showed Lomitapide significantly reduced tumor volume and weight, and inhibited tumor cell proliferation Cell Death Discov. 2023 Feb 11;9(1):60.
Mice HCT116 and HT29 colorectal cancer xenograft models Intraperitoneal injection 10, 20, 25, 50 mg/kg Every 2 days for 10 days To evaluate the effect of Lomitapide on the growth of HCT116 and HT29 xenograft tumors, results showed that Lomitapide significantly inhibited tumor growth. Cell Death Dis. 2022 Jul 12;13(7):603.
C57BL/6J mice Middle cerebral artery occlusion model Oral 0.5 mg/kg Once daily for 14 days Lomitapide significantly increased the survival rate, reduced the neuronal tissue loss, and improved the neurological function. CNS Neurosci Ther. 2022 Dec;28(12):2183-2194.
Mice LDLr−/− mice Oral gavage 1 mg/kg Once daily for 2 weeks To investigate the effect of Lomitapide on cardiovascular function in LDLr?/? mice induced by a high-fat diet. Results showed that Lomitapide significantly reduced, blood glucose, and lipid levels, improved endothelial function, and decreased atherosclerotic plaque area. Antioxidants (Basel). 2023 Jun 16;12(6):1287
Mice High-fat diet-induced obesity model Oral gavage 1 mg/kg Once daily for 2 weeks To investigate the effect of lomitapide on cardiovascular function in obese mice, results showed that lomitapide treatment attenuated the increase in, improved lipid profile and vascular function, and reduced inflammation, ER stress, and oxidative stress. Obesity (Silver Spring). 2022 Apr;30(4):893-901.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.27mL

0.25mL

0.13mL

6.33mL

1.27mL

0.63mL

12.66mL

2.53mL

1.27mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories